ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
U.S. Genomics And Lahey Clinic Announce Collaboration To Study The Role Of MicroRNAs In The Prognosis Of Urologic Cancers
U.S. Genomics Inc. and Lahey
Clinic announce the signing of a discovery agreement to study the role
microRNAs play in the development of urologic cancers. The objective of the
collaboration is to develop more accurate prognoses for bladder and
prostate cancer patients. The collaboration combines U.S. Genomics'
patented Trilogy(R) 2020 platform and Direct(TM) miRNA assay with Lahey
Clinic's expertise in the analysis of tumor progression and experience in
disease management.
"This collaboration is intended to expedite the development of
next-generation molecular diagnostic tests to determine the prognosis of
several major urologic cancers," said John Libertino M.D., Chairman of the
Department of Urology, Lahey Clinic.
"MicroRNAs hold great promise as biomarkers for several disease states,
and we are very pleased to be working with U.S. Genomics to explore these
new diagnostic markers for urologic oncology patients," said Ian
Summerhayes, Ph.D., Executive Director of Research, Lahey Clinic Medical
Center.
"U.S. Genomics is excited about working with Lahey Clinic to study the
potential for microRNA-based tests for the prognosis of bladder and
prostate cancer," said John Canepa, CEO and President of U.S. Genomics.
"Use of our Trilogy(R) 2020 single molecule detection platform and assays
partnered with Lahey Clinic's unique expertise and the guidance of Drs.
Libertino and Summerhayes has the potential to result in significantly more
accurate prognostic tests for these diseases," added Duncan Whitney, VP,
Research & Development (U.S. Genomics).
Bladder Cancer
In the United States, bladder cancer will be diagnosed in more than
61,000 patients by the end of 2006 and there will be more than 13,000
deaths from this disease. Bladder tumors fall into two broad categories
characterized by low-grade papillary tumors, which are usually superficial,
and high-grade tumors that are often invasive. Clinically, superficial
bladder tumors account for 75-80% of the cases, while the remaining 20-25%
are invasive or metastatic at the time of presentation. More than 70% of
patients affected with superficial tumors will have multiple recurrences
and approximately one-third will progress, presenting at a later date with
a more aggressive lesion. At present there are no accurate tests to predict
which non-invasive forms may become invasive. Invasive forms have a much
higher mortality rate and molecular tests based on miRNA signatures are
expected to yield more informative indications than existing tests.
Prostate Cancer
Current methods for evaluating prognosis in prostate cancers remain
imperfect, leading to unnecessary medical procedures. This year in the
United States there will be 234,460 newly diagnosed prostate cancer cases
and approximately 30,000 men will die from the disease. As with many solid
tumors, early diagnosis results in a relatively high cure rate, which
diminishes significantly when prostate cancer escapes beyond the confines
of the gland. However, uncertainty in pathological analysis of biopsies
creates the need for more informative indicators of disease progression and
metastases. It is believed that miRNA assays, can be effective in
differentiating the transition phenotype characterized by the acquisition
of invasive potential.
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring small
RNAs that act as regulators of protein translation. Because many diseases
are caused by the misregulated activity of proteins, detection of
endogenously expressed elements that regulate the production of important
disease-specific proteins, such as miRNAs, become important indicators of
disease, and disease progression. The ability to accurately and precisely
measure expression levels of specific miRNAs has become an important
criterium in both disease research and diagnostics. Detection of miRNAs
using single molecule detection and Trilogy 2020 provides methods for
direct and sensitive quantitation without the need for amplification of
targets.
About U.S. Genomics
U.S. Genomics is pioneering single molecule biology technologies for
life science and biodefense applications by combining advances in
microfluidics, optics, engineering, and novel molecular labeling
strategies. Using its DNA mapping technology, the Company is developing
sophisticated biosensors for the detection and identification of pathogens
and biomarkers in the air, human serum and other biologically relevant
materials. The Company's biodefense focus on airborne pathogens has been
funded in part by $26 million in contracts from the U.S. Department of
Defense and the U.S. Department of Homeland Security. The Company's
Trilogy(R) 2020 platform enables the direct detection and analysis of
individual molecules of DNA, RNA, and proteins without the need for
amplification. U.S. Genomics' portfolio of products will further a greater
understanding of genetics and disease pathways and will ultimately lead to
more effective therapeutics, diagnostics, and biodefense solutions. For
more information about U.S. Genomics, please visit
http://www.usgenomics.com.
Trilogy(R) is a registered trademark and Direct(TM) (as in Direct
miRNA) and U.S. Genomics(TM) are trademarks of U.S. Genomics, Inc.
About Lahey Clinic
Lahey Clinic, a physician-led, nonprofit group practice, is
world-renowned for innovative technology, pioneering medical treatment, and
leading-edge research. A teaching hospital affiliated with Tufts University
School of Medicine, the Clinic provides quality health care in virtually
every specialty and subspecialty, from primary care to cancer diagnosis and
treatment to kidney and liver transplantation. For more information, please
visit our Web site at http://www.lahey.org.
U.S. Genomics Inc.
http://www.usgenomics.com
SUA genomicã ªi Lahey Clinica Anunþarea Colaborare pentru a studia Rolul MicroRNAs In prognosticul Urologic tipuri de cancer - U.S. Genomics And Lahey Clinic Announce Collaboration To Study The Role Of MicroRNAs In The Prognosis Of Urologic Cancers - articole medicale engleza - startsanatate